Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium

Huntington Beach, California and Amsterdam (ots/PRNewswire)
-- Agendia, a world leader in molecular cancer diagnostics, today
announced that leading Agendia and the Netherlands Cancer Institute
researchers will present data from multiple studies at the 2008 San
Antonio Breast Cancer Symposium (SABCS) and Agendia will support,
with an unrestricted grant, the New Frontiers in Individualized
Breast Cancer Therapy symposium. The San Antonio Breast Cancer
Symposium, one of the premiere conferences in breast cancer research
worldwide, takes place December 10th-14th, 2008.

The New Frontiers in Individualized Breast Cancer Therapy
symposium, an important continuing medical education event at the
SABCS, will take place on Saturday, December 13, from 7:30-10 pm, at
the Grand Hyatt, San Antonio. Additionally, a mini-symposium and a
series of poster presentations will highlight results from studies
analyzing Agendia's MammaPrint(R), a FDA-cleared test that identifies
the risk of breast cancer recurrence and provides doctors with the
rationale to assess the benefits of chemotherapy.

Full study results will be discussed at a mini-symposium and
the following embargoed poster sessions and discussions:

Thursday, 12/11/08, 5:30pm - 7:30pm
#1063, Poster Session 1: Prognostic Factors and Biomarkers -
Clinical Testing and Validation, "The 70-gene prognosis profile predicts
early metastases in postmenopausal breast cancer patients." Presenter:
Stella Mook, MD, Netherlands Cancer Institute.
Thursday, 12/11/08, 5:30pm - 7:30pm CST
#1084, Poster Session 1: Prognostic Factors and Biomarkers -
Clinical Testing and Validation, "Benefit of the 70-gene profile for
widely used guidelines: an answer to increased selection for adjuvant
chemotherapy in breast cancer." Presenter: Michael Knauer, M.D.,
Netherlands Cancer Institute.
Friday, 12/12/08, 2pm - 3:30pm CST
Mini-symposium 2, Molecular Profiling for Guiding Therapeutic
Decisions: "RNA".
Presenter: Laura Van 't Veer, PhD, Netherlands Cancer Institute.
Friday, 12/12/08, 5pm - 7pm CST
#305 Poster Discussion 3: Circulating Tumor Cells and Marrow
Micrometastases, "A multi-marker QPCR panel for the detection of
circulating tumor cells predicts survival in breast cancer patients."
Presenter: Laura Van 't Veer, PhD, Netherlands Cancer Institute.
Friday, 12/12/08, 5pm - 7pm CST
#3007, Poster Session 3: Detection/Diagnosis - Diagnostic
Pathology, "Microarray-based determination of ER, PR and HER2 receptor
status: validation and comparison with IHC assessments." Presenter: Paul
Roepman, PhD, Agendia.
Saturday, 12/13/08, 7am - 9am CST
#4171, Poster Session 4: Late Acceptances, "Identification of
a low risk subgroup in Her2-positive breast cancer by the 70-gene
prognosis signature." Presenter: Michaël Knauër, MD, Netherlands Cancer
Institute
Sunday, 12/14/08, 7am - 9am
#6034, Poster Session 6: Prognosis and Response Predictions -
Biomarkers and Other Factors, "Biology of Breast Cancers that Are Screen
Detected vs. Locally Advanced or Young Age Should Inform How We Approach
Early Detection and Prevention." Presenter: Laura Esserman, MD, UCSF
Carol Franc Buck Breast Care Center.

New Frontiers in Individualized Breast Cancer Therapy

The New Frontiers in Individualized Breast Cancer Therapy
symposium updates physicians on the latest information regarding the
development of molecular diagnostic assays for breast cancer and how
to integrate this information into their everyday practices. The
technology behind multigene expression profiling assays will be
discussed, including immunohistochemistry, RT-PCR, and DNA
microarray-based assays. The use of microarray technology in breast
cancer sub-typing will also be covered as well as key clinical data
from prospective validation studies establishing these assays as
prognostic and/or predictive in patients with node-negative
early-stage breast cancer. Comparisons of molecular profiling assays
to traditional clinicopathologic criteria and online algorithms will
be reviewed, and the utility of these assays in patients with
node-positive disease and ongoing clinical trials of multigene assays
in breast cancer will be discussed. For more information please go to
NewFrontiers.CancerLearning.com.

The faculty will consist of:

William F. Symmans, MD, Assistant Professor of Pathology, The
University of Texas M. D. Anderson Cancer Center, Houston, TX

Kelly K. Hunt, MD, F.A.C.S, Professor of Surgery, Department of
Surgical Oncology, Chief Surgical Breast Section, The University of
Texas M. D. Anderson Cancer Center, Houston, TX; Chair Breast
Committee, American College of Surgeons Oncology Group

Rowan T. Chlebowski, MD, PhD, Professor of Medicine, UCLA School
of Medicine, Chief of Medical Oncology at Harbor-UCLA Medical Center,
Torrance, CA.

Emiel J Rutgers, MD, PhD, Professor of Surgery, Department of
Surgical Oncology, Netherlands Cancer Institute/Antoni van
Leeuwenhoek Hospital, Amsterdam, the Netherlands

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index
assay' (IVDMIA) cleared by the U.S. Food and Drug Administration
(FDA). FDA clearance requires clinical and analytical validation and
reporting systems to ensure patient safety issues are addressed.
Highly accurate, MammaPrint identifies patients with early metastasis
- those patients who are likely to develop metastases within five
years following surgery. Several authoritative studies have shown
that chemotherapy particularly reduces early metastasis risk. In
planning treatment, the MammaPrint test result provides a doctor with
a clear rationale to assess the benefit of adjuvant chemotherapy in
addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-certified
service laboratory. All other breast cancer recurrence assays
currently marketed have not been subject to the rigorous FDA
clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatments within reach of patients. Building on a cutting edge
genomics platform for tumor gene expression profiling, the company's
tests aim to help physicians more accurately tailor cancer
treatments. The company markets four products with several new
genomic tests under development. In addition, Agendia collaborates
with pharmaceutical companies to develop highly effective
personalized drugs in the area of oncology. Agendia is based in
Huntington Beach, California, and in Amsterdam, The Netherlands. For
more information please visit http://www.agendia.com.

ots Originaltext: Agendia BV
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media contacts: Hans Herklots, Agendia, +31-20-462-1557 Office,
+31-620-083-509 Mobile, hans.herklots@agendia.com; Valerie Delva,
Ricochet Public Relations, +1-212-679-3300 x131 Office,
+1-917-975-3191 Mobile, vdelva@ricochetpr.com